Michael G Benatar

Professor

  • 7202 Citations
1994 …2023
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Amyotrophic Lateral Sclerosis Medicine & Life Sciences
Myasthenia Gravis Medicine & Life Sciences
Mutation Medicine & Life Sciences
Polyneuropathies Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Prednisone Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2008 2023

Biomarkers
Asymptomatic Diseases
Therapeutics
Organized Financing
Antisense Oligonucleotides
National Institute of Neurological Disorders and Stroke
Clinical Trials
Hispanic Americans
Research Personnel
Research
Validation Studies
Biomarkers
Cerebrospinal Fluid
Intermediate Filaments
Therapeutic Uses
Gene-Environment Interaction
Amyotrophic Lateral Sclerosis
Environmental Exposure
Registries
Mendelian Randomization Analysis
Patient Advocacy
Research
Biomarkers
Exome
Rare Diseases

Research Output 1994 2019

Defining pre-symptomatic amyotrophic lateral sclerosis

Benatar, M. G., Turner, M. R. & Wuu, J., Jan 1 2019, In : Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

Research output: Contribution to journalReview article

Amyotrophic Lateral Sclerosis
Asymptomatic Diseases
Neurodegenerative Diseases
Antisense Oligonucleotides
Genetic Therapy

Editorial: We may need large trials to find treatments for neurodegenerative diseases

Schoenfeld, D. A. & Benatar, M. G., Jan 1 2019, (Accepted/In press) In : Clinical Trials.

Research output: Contribution to journalArticle

Neurodegenerative Diseases
Sample Size
Parkinson Disease
Alzheimer Disease
Clinical Trials
2 Citations (Scopus)

Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis

Clifford, K. M., Hobson-Webb, L. D., Benatar, M. G., Burns, T. M., Barnett, C., Silvestri, N. J., Howard, J. F., Visser, A., Crum, B. A., Nowak, R., Beekman, R., Kumar, A., Ruzhansky, K., Chen, I. H. A., Pulley, M. T., Laboy, S. M., Fellman, M. A., Howard, D. B., Kolb, N. A., Greene, S. M. & 4 othersPasnoor, M., Dimachkie, M. M., Barohn, R. J. & Hehir, M. K., Jan 1 2019, (Accepted/In press) In : Muscle and Nerve.

Research output: Contribution to journalArticle

Thymectomy
Myasthenia Gravis
Plasma Exchange
Intravenous Immunoglobulins
Cholinergic Receptors

ALSUntangled 41: “Eric Is Winning”

The ALSUntangled Group, Jan 2 2018, In : Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 19, 1-2, p. 157-160 4 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Developing treatment guidelines for myasthenia gravis

The MGFA Task Force On Mg Treatment Guidance, Jan 1 2018, In : Annals of the New York Academy of Sciences. 1412, 1, p. 95-101 7 p.

Research output: Contribution to journalReview article

Intravenous Immunoglobulins
Myasthenia Gravis
Immunosuppressive Agents
Protein-Tyrosine Kinases
Muscle